Physician profile
Christine J Fielding
NPI 1811981608
$34,968.17
in general payments reported to CMS, 2019-2025
14 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,554 · 2020: $447 · 2021: $8,862 · 2022: $1,877 · 2023: $16K · 2024: $4,978 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $7,263 · Food and Beverage: $3,308 · Entertainment: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,540.00 |
| Consulting Fee | $7,262.50 |
| Food and Beverage | $3,308.13 |
| Entertainment | $117.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $18,594.89 | 2019-2025 | Da Vinci Sp, Da Vinci Surgical System |
| Reshape Lifesciences INC. | $9,537.27 | 2021-2024 | |
| Medtronic, INC. | $3,183.03 | 2021-2025 | Signia |
| W. L. Gore & Associates, INC. | $969.61 | 2019-2023 | Gore Synecor Biomaterial |
| Novo Nordisk INC | $789.34 | 2020-2025 | Wegovy |
| Ethicon US, LLC | $778.72 | 2019-2022 | |
| Intra-Sana Laboratories | $393.70 | 2024-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Covidien LP | $161.81 | 2019 | |
| Lilly USA, LLC | $148.38 | 2022-2025 | Zepbound, Mounjaro |
| Baxter Healthcare | $124.99 | 2022 | |
| Currax Pharmaceuticals LLC | $115.95 | 2022-2023 | Contrave, Onzetra Xsail |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.95 | 2020 | |
| Levita Magnetics International Corp | $70.48 | 2019 | |
| Heron Therapeutics, INC. | $24.05 | 2023 | Aponvie |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Fielding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.